Xolair denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for xolair are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Xolair: Prior Authorization Required

UHC requires prior authorization (PA) for Xolair (omalizumab) before it will cover the drug. A "prior-auth-required" denial means either that no PA was submitted before the prescription was filled, that the PA was submitted but not yet approved when the claim processed, or that the PA was denied on the merits. Each scenario has a different appeal path.

## Why This Is Appealable

If the PA was never submitted, your prescriber can submit one now and, if approved, UHC will sometimes retroactively cover a recently filled prescription — ask explicitly about retroactive authorization. If the PA was denied, you have the right to appeal that denial through both an internal and external review process. PA denials for Xolair are frequently overturned when the clinical documentation is thorough and directly addresses UHC's stated criteria.

## Federal Appeal Framework

• Internal appeal: Available under ACA §2719 and ERISA §503. File within the timeframe on your denial letter (commonly 180 days). UHC must decide standard appeals within 30 days for prospective (not-yet-received) treatment; 60 days for post-service.
• Expedited appeal: If your condition is urgent, request an expedited internal appeal — decision is required within 72 hours.
• External review: If the internal appeal fails, an IRO can independently review UHC's decision. The external review window is typically up to four months from final internal denial. Expedited external review is available for urgent situations.

## Documentation to Collect

1. Diagnosis confirmation — chart notes, specialist records, and lab/allergy/pulmonary testing that establish your diagnosis. 2. Prior-treatment history — dates and outcomes of every previous therapy you tried, showing why standard alternatives were insufficient. 3. Clinical severity assessment — objective measures from your chart (e.g., symptom scores, exacerbation frequency, quality-of-life impact) showing the severity of your condition. 4. FDA prescribing label and UHC policy — identify the exact criteria UHC requires for PA approval; download UHC's current Xolair medical policy from their provider portal. 5. Letter of medical necessity — your prescriber should address each UHC criterion point-by-point, citing specific chart dates and findings.

## Criteria-Mapping Structure

List every PA criterion from UHC's policy verbatim. Next to each, record the specific clinical fact from your chart that satisfies it — including the date, provider name, and source document. Submit this as an exhibit alongside the medical necessity letter.

## Practical Tips

Ask your prescriber's office whether they have a specialty-pharmacy liaison who handles UHC PA disputes — these staff members submit appeals regularly and know which supporting documents UHC reviewers prioritize. Also ask Genentech (Xolair's manufacturer) about their patient support program, which sometimes provides appeals assistance.